Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA Onxeo announced its plan for further development of AsiDNA, its first-in-class signal interfering DNA molecule which breaks the cycle of tumor DNA repair to induce cancer cell death.
Drug Research > Drug Discovery & Development > News
Hengrui Therapeutics unveils $100m investment from HR Bio Holdings for global clinical development Hengrui Therapeutics (HTI) has signed an agreement with HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui Medicine Co. Ltd. (JHM) and an undisclosed blue chip investment firm, regarding a $100 million investment in HTI.
Drug Research > Drug Discovery & Development > News Gene-editing firm CRISPR Therapeutics raises additional $38M in Series B Financing By PBR Staff Writer
Gene-editing firm CRISPR Therapeutics has raised an additional $38m as part of series B financing, bringing the total investment in the round to about $140m.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Pfizer acquires Anacor Pharmaceuticals for $5.2bn
By PBR Staff Writer
Pfizer has acquired Anacor Pharmaceuticals, which is engaged in the discovery, development and commercialization of novel small-molecule therapeutics, for $5.2bn.
Drug Research > Drug Discovery & Development > News
Yumanity Therapeutics and New York Stem Cell Foundation Research Institute form discovery collaboration
Yumanity Therapeutics announced a discovery collaboration with the New York Stem Cell Foundation (NYSCF) Research Institute, a non-profit organization dedicated to accelerating cures for major diseases through stem cell research.
Drug Research > Drug Discovery & Development > News
Compugen discloses lead therapeutic candidate for CGEN-15029 immuno-oncology program
Compugen disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN-15029 target program.
Drug Research > Drug Discovery & Development > News
GW Pharmaceuticals selects infantile spasms for Epidiolex development program
GW Pharmaceuticals has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.
Drug Research > Drug Discovery & Development > News
F2G raises $60m in funding to progress antifungal agents development
By PBR Staff Writer
UK-based antifungal drug discovery and development firm F2G has raised $60m in financing to progress development of novel antifungal agents.
Drug Research > Drug Discovery & Development > News
Blade Therapeutics raises $45m Series B Financing
Blade Therapeutics announced the closing of a Series B financing led by Deerfield Management, that will bring $45m into the company when all milestones are completed.
Drug Research > Drug Discovery & Development > News
Crown Bioscience strengthens global immuno-oncology platform
Crown Bioscience has strengthened its global Immuno-Oncology Platform at all its key facilities in Europe, US, and Asia to support client's needs with a comprehensive collection of validated models and services for in vivo pharmacodynamic and efficacy studies.
Drug Research > Drug Discovery & Development > News
Carbylan Therapeutics, KalVista Pharmaceuticals enter into share purchase agreement
Carbylan Therapeutics and KalVista Pharmaceuticals have entered into a definitive share purchase agreement pursuant to which the shareholders of KalVista will become the majority owners of Carbylan.
Drug Research > Drug Discovery & Development > News
Rgenix announces $33m series B financing to develop cancer therapeutics
Rgenix, a cancer therapeutics company developing first-in-class drugs targeting novel cancer pathways, announced a $33m Series B financing led by Novo A/S and Sofinnova Partners, with participation from existing investors including Partnership Fund for New York City, Alexandria Venture Investments, and Conegliano Ventures LP.
Drug Research > Drug Discovery & Development > News
Biopharmaceutical firm Allecra Therapeutics raises EUR22m funding
By PBR Staff Writer
Biopharmaceutical firm Allecra Therapeutics has raised €22m in a series B investment round led by Delos Capital.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests